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See related article on page 891. It is often difficult, or even impossible, for surgeons to answer someimportant questions in the context of a prospective, randomized clinicaltrial. Although the randomized trial is the gold standard for comparing twotherapeutic interventions, a number of statistical, practical, and ethicalconsiderations, combined with our own preconceived ideas, usually preventthe contemplation of a randomized trial. A common problem may be that
limited patient numbers or small differences between treatments may prevent a large
enough trial to provide a valid statistical power to detect legitimate treatment
differences. In fact, the majority of randomized surgical trials are flawed by this very
lack of a power calculation in the original trial design.1
In other cases, a preponderance of phase II clinical trial data may make it appear
unethical to assign patients to one of the arms of a randomized study. This is often
difficult to disconnect from the separate problem of surgeon bias. However, these
are distinct and should not be confused or intertwined. When a preponderance of the
informed medical community believes that one treatment is better on the basis of
clinical experience and scientific outcomes, random treatment assignment becomes
unethical. However, if a given physician, or group of physicians, believes strongly
in treatment efficacy, yet is balanced by an informed but skeptical group of
physicians, this creates the setting of clinical equipoise, a condition of legitimate
professional uncertainty about the optimal treatment. We as surgeons have been
quick to accept simple case series, often from a single institution, as adequate proof
of efficacy, limiting our ability or willingness to subject these questions to the more
rigorous examination of a randomized clinical trial.1
Dr Zuckermann and his colleagues2 are to be commended for the discipline of the
design of their study comparing cyclosporine A (CSA/MMF) to tacrolimus (TAC/
MMF), both combined with mycophenolate mofetil and steroids. Their group
identified a potential improved immunosuppressive drug regimen on the basis of
knowledge of drug mechanism, combined with small pilot data published by other
groups. By addressing this in a prospective randomized trial, they have provided us
with much clearer outcomes than would have been accomplished by continued ad
hoc immunosuppressive management. In this case, the trial did not display a
treatment difference, but this should not be too surprising, despite a sincere effort of
scientific objectivity. There are four limitations in trial design that may have
prevented this trial from showing differences between the two treatment assign-
ments.
First, a single institution study may not provide an adequate patient base to detect
legitimate treatment differences. Ideally, one would estimate the degree of expected
differences in the primary outcome and perform power calculations to determine the
necessary cohort size. In a series like this, these calculations may have led the
authors to abandon the study at the outset, rather than exert effort on a course of
investigation that had no potential to reveal treatment differences. On the other
hand, it may have led the authors to seek other institutions to collaborate with in
order to achieve an adequate sample size. These considerations of statistical power
are not revealed in the article, but it would require major differences in outcomes to
be detected by 37 patients in each treatment group.
The second problem is closely related to the small sample size as well. The
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authors were very careful to stratify cytomegalovirus status
and cystic fibrosis diagnosis between treatment groups.
However, other potentially relevant variables, such as sex,
diagnosis, or type of lung transplant procedure, were not
equal between groups. Although none of these reached
statistical significance, confounding variables like these
could easily skew a small study and result in an inaccurate
conclusion.
The third difficulty is in the analysis of treatment failure.
The major benefit of a randomized trial is that it allows the
most direct comparison between treatment groups—first by
minimizing the impact of unsuspected variables and second
by observing and analyzing the patients throughout the
study, whether or not they were really able to complete their
assigned treatment. This “intention to treat” analysis main-
tains the perspective of how the treatment will work in the
real world. If we analyze only the patients whose assigned
treatment was successfully completed, we will overestimate
the benefit of that therapy, and in fact we may lose the most
valuable data on what happens to the remaining patients.
For this reason, censoring patients who drop out of a trial, or
who cross over to the other arm of the trial, undermines the
major strength of randomizing patients. In the case of the
study by Zuckermann and associates, 4 patients from the
cyclosporine group crossed over to tacrolimus because of
recurrent rejection, at which time they were censored from
further analysis. Indeed, examination of these patients and
inclusion of them in the cyclosporine statistics, even after
crossover, provide the most legitimate comparison of the
true impact of each treatment assignment.
Despite these methodologic problems, probably the most
important reason that this study did not display a treatment
difference is due to the underlying scientific question. It is
conceptually understandable why the CSA/MMF and TAC/
MMF groups did not show significant outcome differences.
Cyclosporine A binds to cyclophyllin and tacrolimus to
FK-binding protein. They have different potencies and are
dosed to different adjusted trough levels. However, they
have the same basic mechanism of action—inhibition of the
calcium-calmodulin dependent phosphatase, calcineurin.
Using different compounds to block the same step in the
response to alloantigen would not be expected to show
marked differences in outcome.
Azathioprine interferes with purine synthesis, as does
mycophenylate mofetil. However, mycophenylate mofetil is
considerably more potent. Mycophenylate mofetil blocks
inosine monophosphate dehydrogenase, which is required
for purine synthesis. Unlike other blood and parenchymal
cells, T and B lymphocytes use the inosine monophosphate
dehydrogenase pathway exclusively for purine synthesis.
As a result, mycophenylate mofetil should produce less
neutropenia at doses that are highly effective against T and
B cell proliferation. The studies cited by the authors attest to
the advantages of tacrolimus and mycophenylate mofetil
individually. However, it is likely that using mycophenylate
mofetil in place of azathioprine would produce a benefit that
could mask or at least confound any additional benefit of
tacrolimus.
Each transplant center will likely continue to define its
own preferences for calcineurin inhibitors and blockers of
purine metabolism. However, notable advances in the fight
against acute rejection and bronchiolitis obliterans will have
to come from novel treatment strategies, not merely refine-
ments of existing protocols. Sirolimus (rapamycin) is a
product of a Streptomyces species that binds to the same
intracellular protein as tacrolimus, the so-called FK-binding
protein, yet it does not inhibit calcineurin activity. Its effects
arise from blocking cell cycle progression and calcium-
independent signaling pathways in T and B cells. It may
also inhibit mesenchymal cell proliferation and thereby
offer a theoretical advantage in the prophylaxis against the
fibroproliferative response to transplantation (also known as
obliterative bronchiolitis). Despite reports that support the
use of rapamycin in rescue therapy, prospective randomized
data attesting to the efficacy of rapamycin in clinical lung
transplantation to date is not compelling.
Antithymocyte globulin was shown to reduce the inci-
dence of acute rejection and potentially affect obliterative
bronchiolitis in the study from Duke.3 Recent studies have
suggected that OKT-3, antithymocyte globulin, and inter-
leukin 2 receptor antagonists produce similar reductions in
rejection.4 The safety of interleukin 2 receptor antagonists
may indeed be slightly better. In general, cytolytic therapies
have a basic flaw: targeting common T-cell receptors re-
quired for rejection will also interfere with their ability to
facilitate the development of tolerance.
Minimizing inflammation associated with implantation
will theoretically limit lymphocyte trafficking into the allo-
grafts. Efforts to eradicate ischemia-reperfusion injury can
reduce major histocompatibility complex-II antigen expres-
sion and will likely have lasting beneficial effects on acute
and chronic rejection.
Ultimately, long-term optimization of graft function
and viability will depend on the development of toler-
ance. This appears to be possible through the establish-
ment of chimerism. Early results with donor-specific
bone marrow transfusion suggested decreased acute re-
jection and bronchiolitis obliterans syndrome.5 However,
how best to prepare stem cells for engraftment, the re-
quirements for any facilitating marrow-derived cells, and
the optimal pro-tolerant immunosuppressive all have yet
to be defined. This is an exciting and novel area of lung
transplant research.
Clearly the study in this issue represents an effort to
address a current area of relative controversy. The au-
thors have conducted a thoughtful randomized trial, al-
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though with flaws that may limit its interpretation. How-
ever, the real challenge for us to make significant
improvements in long-term lung transplant outcome will
require the investigation of novel immunosuppressive
strategies and not merely refinements of conventional
treatments.
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